Humanigen, Inc. (OTCQB:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab has announced the appointment of Bob Atwill, to the newly created role of Head of Asia-Pacific, effective immediately.
The new hire will report to Dr Cameron Durrant, Humanigen’s chief executive officer of and will initially serve on a consultancy basis.
Atwill has more than 30 years of experience in the global healthcare industry across the pharmaceutical, biotechnology and cellular therapy sectors. He began his career at GlaxoSmithKline and Sanofi-Synthélabo prior to holding senior executive and consulting roles at Mesoblast, Benitec Biopharma and a number of other US, European and Australian-listed biotechnology companies.
He currently serves as Principal at Eaton Square, a cross-border M&A and capital service provider, in its biotechnology practice, based in the Melbourne office.
In a statement, Durrant said: "We have several partner-funded clinical trials either underway or in late-stage planning in Australia. Bob's business development and clinical trial expertise, coupled with his deep industry network and relationships with multiple leading hospitals, make him ideally suited to build on our existing work and to help us evaluate and pursue potential strategic partnerships in the region."
"Bob has worked in COVID-19 and other virology areas, graft-versus-host disease, immuno-oncology and cell and gene therapy with leading companies, and we believe his scientific and market understanding will be valuable to Humanigen's strategic long-term and global growth," Durrant added.
Atwill said, "There has never been a more important time to rapidly commercialize valuable technologies in the healthcare and biotechnology industry, especially those that will have the potential to play a critical role in mitigating the impact of the COVID-19 pandemic. I am honoured to assist in progressing lenzilumab and the Humanigen pipeline in Australia and more broadly across the Asia-Pacific Region."
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
Lenzilumab, is the company's proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.
Contact the author at email@example.com